出國報告(出國類別:開會)

# 2024年新加坡亞太風濕病學會聯盟醫學會議心得報告

服務機關:高雄榮民總醫院兒童醫學部

姓名職稱:翁根本/科主任

派赴國家:新加坡

出國期間:2024/08/20-2024/08/26

報告日期:2024/09/10

#### 摘要

2024年亞太風濕病學會聯盟醫學會議於新加坡舉行,時間是 2024年8月21日至2024年8月25日,本人有幸參與此會議,發表論文『川崎氏症和兒童多系統發炎症後群與新冠肺炎感染相關性』,收穫良多。上千多位來自世界各國的醫師專家來參與這個盛會,會議內容是探討各種風濕免疫疾病、血管炎和新冠肺炎相關免疫疾病問題,非常多樣豐富,且有機會和其他國家專家交流合作,個人有吸收到相當多新知,對於照顧川崎氏症病童有相當多的幫助。本人和其他各國學者有深入討論,收穫很多,這些交流經驗有助於資料整理和論文發表。參加會議的每一天,都有滿滿收穫和豐富資料,依依不捨離開新加坡,希望很快就能再和這些學者做學術經驗上的交流。

**關鍵字:**川崎氏症、兒童多系統發炎症後群、新冠肺炎感染

## 目次

一、目的	3
二、過程	4
三、心得及建議	5
<b>阶錄</b>	5

2024年亞太風濕病學會聯盟醫學會議於新加坡舉行,時間是 2024年8月21日至2024年8月25日,本人參與此會議,並發表論文『川崎氏症和兒童多系統發炎症後群與新冠肺炎感染相關性』。

#### 二、過程

2024-8-20

由桃園搭機至新加坡。

2024-8-21

到會場報到,並參加會議,今天是超音波專題討論會。

2024-8-22

今天會議主題是紅斑性狼瘡疾病、免疫學、血管炎等題目,做深入教學和討論,其中血管 炎專題討論會,對我的臨床照顧和研究幫助很大。

2024-8-23

今天會議主題是風溼性關節炎影像檢查和標靶藥物治療、紅斑性狼瘡疾病相關腎病處置、 兒科風溼免疫疾病、血管炎新知、和精準檢測和資料分析等精彩演講;另一個重頭戲是發表下 列論文『川崎氏症和兒童多系統發炎症後群與新冠肺炎感染相關性』,本人和其他各國學者有 深入討論,收穫很多,這些交流經驗有助於資料整理和論文發表。

2024-8-24

今天會議主題是關節炎和紅斑性狼瘡疾病診斷治療新進展,以及如何將血管炎治療到最好的狀態,我的研究重心川崎氏症,就是一種血管發炎疾病,這方面的新知,對我照顧病人和做相關研究的幫助很大。

2024-8-25

今天會議主題是探討發炎性關節炎、兒科自體免疫疾病、和骨質疏鬆症等,聽完這些演講, 收穫很多。

2024-8-26


由新加坡搭機回國。

#### 三、心得及建議

本人参加這次會議,和其他各國學者有深入討論,收穫很多,這些交流經驗有助於資料整理和論文發表。參加會議的每一天,都有滿滿收穫和豐富資料,依依不捨離開新加坡,希望很快就能再和這些學者做學術經驗上的交流。建議大家可以整理自己研究心得,積極參與國際醫學會議,增廣自己見聞,院方也能給予適當獎勵補助。

#### 附錄

## Program at a Glance





#### Risks of KD and MIS-C in Pediatric Patients with COVID-19 Infection: A TriNetX Based Cohort Study

Ken-Pen Weng, M.D.; Cheng-Chung James Wei, Ph.D.\*

Department of Pediatrics, Kaohslung Veterans General Hospital, Kaohslung, Talwan, ROC "Institute of Medicine, Chung Shan Medical University, Taichung, Talwan, ROC

#### **Abstract**

Background: The associations of COVID-19 with Kawasaki disease (KD) and multisystem inflammatory syndrome in children (MIS-C) remain unclear. Few large-scale studies have estimated the cumulative incidence of MIS-C and KD after COVID-19 in children.

Methods: Data were obtained from TriNetX, After propensity score matching was completed, data from 258,645 patients with COVID-19 (COVID-19 group) and 258,645 patients without COVID-19 (non-COVID-19 group) were analyzed using Cox regression. Hazard ratio (HR), 95% confidence interval (CI), and cumulative incidence of MIS-C and KD were calculated for both groups. Stratified analysis was performed to validate the results.

Results: After matching for age at baseline and sex, the risks of MIS-C and KD were higher in the COVID-19 group than in the non-COVID-19 group (HR: 3.023 [95% CI: 2.323 to 3.933] and 1.736 [95% CI: 1.273 to 2.369], respectively) (Figure 1. and Figure 2.). After matching for age at baseline, sex, race, ethnicity, and comorbidities, the risks of MIS-C and KD remained significantly higher in the COVID-19 group than in the non-COVID-19 group (HR: 2.899 [95% CI: 2.173 to 3.868] and 1.435 [95% CI: 1.030 to 2.000]). When stratified by age, the risk of MIS-C was higher in the COVID-19 group—for patients aged > 5 years and ≤ 5 years (HR: 2.399 [95% CI: 1.683 to 3.418] and 2.673 [95% CI: 1.737 to 4.112], respectively)—than in the non-COVID-19 group. However, the risk of KD was elevated only in patients aged ≤ 5 years (HR: 1.808; 95% CI: 1.203 to 2.716). When stratified by COVID-19 vaccination status, the risks of MIS-C and KD were elevated in unvaccinated patients with COVID-19 (HR: 2.406 and 1.835, respectively) (Table 1.).

Conclusion: Patients with COVID-19 who are aged < 18 and ≤ 5 years have increased risks of MIS-C and KD, respectively. Further studies are required to confirm the role of COVID-19 in the pathogenesis of MIS-C and KD.

## Figure 1. Kaplan—Meier curves of MIS-C between COVID-19 and non-COVID-19 groups.



## Figure 2. Kaplan-Meier curves of Kawasaki disease between COVID-19 and non-COVID-19 groups.




Table 1. Subgroup analysis stratified by sex, age, race, ethnicity, infection related comorbidities, and COVID-19 vaccination.

Š.	HRs (95% Cls)	
	MIS.C-	
Sex .		
Male	2.421 (1.700.3 448)	1.062 (1.057, 2.612)
Female	3.658 (2.249, 5.950)	1.159 (0.764, 1.908)
Age (years)		
55	2 673 (1.737, 4.112)	1.808 (1.203, 2.716)
±5 >6	2.390 (1.683, 3.418)	1 566 (0.973, 2.520)
Race		
Black	1.687 (1.078, 2.042)	0.999 (0.469, 2.128)
White	2.938 (1.892, 4.583)	2.520 (1.511, 4.204)
Aelan		1.549(0.259.9.272)
Other	2.202(1.405.3.453)	1 931 /1 009 1 009)
Ethnicity		
Hispanic or Latino	2.575(1.533.4.325)	2 169(1 238 3 801)
Other	2.543(2.076.3.888)	1.290/0.896 (1.841)
Comorbidities		
Influenza	5.153 (1.979,13.418)	2.306/0.886.6.000)
Certain infectious and parasitic diseases	1.759(1.421,2.178)	1.201(0.909,1.588)
COVID-19 veccination		
With	- 1	2.063 (0.187, 22.750)
Without	2 406 (1 878, 3 083)	1.835 (1.336, 2.522)





#APLAR24



